202 related articles for article (PubMed ID: 26181761)
1. Rapid Intraoperative Molecular Characterization of Glioma.
Shankar GM; Francis JM; Rinne ML; Ramkissoon SH; Huang FW; Venteicher AS; Akama-Garren EH; Kang YJ; Lelic N; Kim JC; Brown LE; Charbonneau SK; Golby AJ; Sekhar Pedamallu C; Hoang MP; Sullivan RJ; Cherniack AD; Garraway LA; Stemmer-Rachamimov A; Reardon DA; Wen PY; Brastianos PK; Curry WT; Barker FG; Hahn WC; Nahed BV; Ligon KL; Louis DN; Cahill DP; Meyerson M
JAMA Oncol; 2015 Aug; 1(5):662-7. PubMed ID: 26181761
[TBL] [Abstract][Full Text] [Related]
2. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
[TBL] [Abstract][Full Text] [Related]
3. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
4. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
Kanamori M; Kikuchi A; Watanabe M; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Kumabe T; Kure S; Tominaga T
J Neurosurg; 2014 Jun; 120(6):1288-97. PubMed ID: 24745708
[TBL] [Abstract][Full Text] [Related]
5. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
7. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
9. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of [
Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
[TBL] [Abstract][Full Text] [Related]
13. A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.
Koriyama S; Nitta M; Kobayashi T; Muragaki Y; Suzuki A; Maruyama T; Komori T; Masui K; Saito T; Yasuda T; Hosono J; Okamoto S; Shioyama T; Yamatani H; Kawamata T
Brain Tumor Pathol; 2018 Jul; 35(3):159-167. PubMed ID: 29980868
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
15. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.
Aibaidula A; Zhao W; Wu JS; Chen H; Shi ZF; Zheng LL; Mao Y; Zhou LF; Sui GD
J Neurosurg; 2016 Jun; 124(6):1611-8. PubMed ID: 26544771
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
17. Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.
Barritault M; Picart T; Poncet D; Fenouil T; d'Hombres A; Gabut M; Guyotat J; Jouanneau E; Ameli R; Joubert B; Streichenberger N; Vasiljevic A; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2020 Sep; 87(4):E513-E519. PubMed ID: 32107549
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
19. Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood.
Huse JT
Surg Pathol Clin; 2016 Sep; 9(3):379-90. PubMed ID: 27523967
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
